-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Avalo Therapeutics (NASDAQ:AVTX) Versus Forward Pharma A/S (NASDAQ:FWP) Head-To-Head Contrast
Avalo Therapeutics (NASDAQ:AVTX) Versus Forward Pharma A/S (NASDAQ:FWP) Head-To-Head Contrast
Forward Pharma A/S (NASDAQ:FWP – Get Rating) and Avalo Therapeutics (NASDAQ:AVTX – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.
Earnings and Valuation
This table compares Forward Pharma A/S and Avalo Therapeutics' top-line revenue, earnings per share and valuation.
Get Forward Pharma A/S alerts:Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Forward Pharma A/S | N/A | N/A | -$1.89 million | N/A | N/A |
Avalo Therapeutics | $5.40 million | 7.72 | -$84.38 million | N/A | N/A |
Forward Pharma A/S has higher earnings, but lower revenue than Avalo Therapeutics.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Forward Pharma A/S and Avalo Therapeutics, as reported by MarketBeat.Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Forward Pharma A/S | 0 | 0 | 0 | 0 | N/A |
Avalo Therapeutics | 0 | 1 | 2 | 0 | 2.67 |
Avalo Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 577.20%. Given Avalo Therapeutics' higher possible upside, analysts plainly believe Avalo Therapeutics is more favorable than Forward Pharma A/S.
Volatility & Risk
Forward Pharma A/S has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.
Profitability
This table compares Forward Pharma A/S and Avalo Therapeutics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Forward Pharma A/S | N/A | N/A | N/A |
Avalo Therapeutics | -1,896.95% | -449.27% | -106.25% |
Institutional & Insider Ownership
13.0% of Forward Pharma A/S shares are held by institutional investors. 71.5% of Forward Pharma A/S shares are held by insiders. Comparatively, 45.4% of Avalo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Forward Pharma A/S beats Avalo Therapeutics on 7 of the 10 factors compared between the two stocks.
About Forward Pharma A/S
(Get Rating)
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
About Avalo Therapeutics
(Get Rating)
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
Forward Pharma A/S (NASDAQ:FWP – Get Rating) and Avalo Therapeutics (NASDAQ:AVTX – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.
前进医药A/S(纳斯达克:FWP-GET评级)和阿瓦洛治疗(纳斯达克:AVTX-GET评级)都是小盘医疗公司,但哪一家更好?我们将根据分析师建议的实力、盈利能力、股息、估值、风险、收益和机构所有权对这两家公司进行比较。
Earnings and Valuation
收益和估值
This table compares Forward Pharma A/S and Avalo Therapeutics' top-line revenue, earnings per share and valuation.
此表比较了Forward Pharma A/S和Avalo Treeutics的营收、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Forward Pharma A/S | N/A | N/A | -$1.89 million | N/A | N/A |
Avalo Therapeutics | $5.40 million | 7.72 | -$84.38 million | N/A | N/A |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
正向医药应收账款 | 不适用 | 不适用 | -189万元 | 不适用 | 不适用 |
阿瓦洛治疗公司 | 540万美元 | 7.72 | -8,438万元 | 不适用 | 不适用 |
Forward Pharma A/S has higher earnings, but lower revenue than Avalo Therapeutics.
Forward Pharma A/S的收益高于Avalo治疗公司,但收入低于Avalo治疗公司。
Analyst Recommendations
分析师建议
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Forward Pharma A/S | 0 | 0 | 0 | 0 | N/A |
Avalo Therapeutics | 0 | 1 | 2 | 0 | 2.67 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
正向医药应收账款 | 0 | 0 | 0 | 0 | 不适用 |
阿瓦洛治疗公司 | 0 | 1 | 2 | 0 | 2.67 |
Avalo Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 577.20%. Given Avalo Therapeutics' higher possible upside, analysts plainly believe Avalo Therapeutics is more favorable than Forward Pharma A/S.
阿瓦洛治疗公司的共识目标价为30美元,暗示潜在上涨577.20%。考虑到Avalo治疗公司更有可能的上行空间,分析师们显然认为Avalo治疗公司比Forward Pharma A/S更有利。
Volatility & Risk
波动性与风险
Forward Pharma A/S has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.
Forward Pharma A/S的贝塔系数为1.36,这意味着其股价的波动性比标准普尔500指数高36%。相比之下,Avalo Treateutics的贝塔系数为1.3,这意味着其股价的波动性比标准普尔500指数高30%。
Profitability
盈利能力
This table compares Forward Pharma A/S and Avalo Therapeutics' net margins, return on equity and return on assets.
此表比较了Forward Pharma A/S和Avalo Treeutics的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Forward Pharma A/S | N/A | N/A | N/A |
Avalo Therapeutics | -1,896.95% | -449.27% | -106.25% |
净利润率 | 股本回报率 | 资产回报率 | |
正向医药应收账款 | 不适用 | 不适用 | 不适用 |
阿瓦洛治疗公司 | -1,896.95% | -449.27% | -106.25% |
Institutional & Insider Ownership
机构与内部人持股
13.0% of Forward Pharma A/S shares are held by institutional investors. 71.5% of Forward Pharma A/S shares are held by insiders. Comparatively, 45.4% of Avalo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
机构投资者持有13.0%的Forward Pharma A/S股票。71.5%的Forward Pharma A/S股份由内部人士持有。相比之下,Avalo Treateutics 45.4%的股份由内部人士持有。强大的机构持股表明,捐赠基金、大型基金管理公司和对冲基金相信,一家公司的长期表现将好于大盘。
Summary
摘要
Forward Pharma A/S beats Avalo Therapeutics on 7 of the 10 factors compared between the two stocks.
Forward Pharma A/S在两只股票比较的10个因素中有7个击败了Avalo Treateutics。
About Forward Pharma A/S
关于Forward Pharma A/S
(Get Rating)
(获取评级)
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
Forward Pharma A/S没有重大操作。此前,它是一家生物制药公司,专注于开发用于治疗炎症和神经系统适应症的富马酸二甲酯的FP187专利配方。Forward Pharma A/S成立于2005年,总部设在丹麦哥本哈根。
About Avalo Therapeutics
关于Avalo Treateutics
(Get Rating)
(获取评级)
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Avalo治疗公司是一家临床阶段的精密药物公司,为免疫学、免疫肿瘤学和罕见遗传病方面未得到满足的临床需求的患者发现、开发和商业化靶向治疗药物。该公司开发了AVTX-002,这是一种完全人类抗光的单抗,正在进行第二阶段临床试验,用于治疗非嗜酸性哮喘以及炎症性肠道疾病,包括中到重度克罗恩病和溃疡性结肠炎;以及第三阶段临床试验,用于治疗新冠肺炎急性呼吸窘迫综合征。该公司还致力于开发AVTX-007,这是一种完全人类抗IL-18的单抗,正在进行第一阶段临床试验,用于治疗斯蒂尔病,包括成人发病的斯蒂尔病和全身性幼年特发性关节炎。它的第三阶段临床试验中针对罕见遗传病的产品包括治疗磷酸葡萄糖变位酶1缺乏症(PGM1)的D-半乳糖底物替代疗法AVTX-801,也称为PGM1-CDG;以及治疗LADII的L-岩藻糖底物替代疗法AVTX-803,也称为SLC35C1-CDG。该公司前身为Cerecor Inc.,并于2021年8月更名为Avalo治疗公司。Avalo治疗公司成立于2011年,总部设在马里兰州罗克维尔。
Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
接受Forward Pharma A/S日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Forward Pharma A/S和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧